NL-OMON46133已完成2 期
A phase IIa randomized, placebo controlled, double blinded study to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. - iHIVARNA phase IIa study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. * 18 years of age;
- •2. Voluntarily signed informed consent;
- •3. Proven HIV-1 infection (with documented antibodies against HIV-1 and a detectable plasma HIV-1 RNA before initiation of therapy);
- •4. On stable treatment with cART regimen (antiretroviral therapy consisting of at least three registered antiretroviral agents) for at least 3 years;
- •5. Nadir CD4+ * 350 cells/*l (up to 2 occasional determinations * 350 cells/*l are allowed);
- •6. Current CD4+ cell count * 450 cells/*l;
- •7. HIV-RNA below 50 copies/mL in the last 6 months prior to randomization, during at least two measurements (occasional so called *blips* * 500 copies/mL are permitted);
- •8. If sexually active, willing to use a reliable method of reducing the risk of transmission to their sexual partners during treatment interruption (including PrEP).
- •a. For heterosexually active female, using an effective method of contraception with partner (combined oral contraceptive pill; injectable or implanted contraceptive; IUD/IUS; consistent record with condoms; physiological or anatomical sterility (in self or partner) from 14 days prior to the first vaccination until 4 months after the last vaccination.
- •b. For heterosexually active male, using an effective method of contraception with their partner from the first day of vaccination until 4 months after the last vaccination.
排除标准
- •1. Treatment with non-cART regimen prior to cART regimen;
- •2. Previous failure to antiretroviral and/or mutations conferring genotypic resistance to antiretroviral therapy;
- •3. Non-subtype B HIV infection;
- •4. Active Hepatitis B virus and/or Hepatitis C virus co-infection;
- •5. History of a CDC class C event (see appendix A);
- •6. Pregnant female (screened with a positive pregnancy test), lactating or intending to become pregnant during the study;
- •7. History of malignancy * 30 days (extended period on the clinical assessment of the investigator) prior to screening;
- •8. Active infection with fever (38°C or above) * 10 days of screening and/or first vaccination;
- •9. Therapy with immunomodulatory agents (e.g. systemic corticosteroids), including cytokines (e.g. IL-2), immunoglobulins and/or cytostatic chemotherapy * 90 days prior to screening. This does not include seasonal influenza, hepatitis B and/or other travel related vaccines;
- •10. Congenital, acquired or induced coagulation disorders, such as thrombocytopenia (thrombocytes < 150x109/L) and/or current use of anti-coagulant medication (e.g. coumarins, inhibitors of Xa); Usage of NSAIDs (including acetylsalicylic acid) is allowed, however it is advised to interrupt therapy 10 days ahead of vaccination;
- •11. Usage of any investigational drug * 90 days prior to study entry;
- •12. An employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, or is a family member of an employee or the investigator
- •13. Any other condition, which, in the opinion of the investigator, may interfere with the evaluation of the study objectives
研究者
相似试验
进行中（未招募）
1 期
Phase II vaccination trial in HIV-1 infected subjectsChronic HIV-1 infectionMedDRA version: 19.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2016-002724-83-BEErasmus MC70
进行中（未招募）
1 期
Phase II vaccination trial in HIV-1 infected subjectsChronic HIV-1 infectionMedDRA version: 19.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2016-002724-83-ESErasmus MC70
进行中（未招募）
1 期
Phase II vaccination trial in HIV-1 infected subjectsEUCTR2016-002724-83-NLErasmus MC33
招募中
2 期
A Phase II study of M528101 for postherpetic neuralgiaJPRN-jRCT2031220415Tomoyuki Nishiura18
招募中
2 期
A Phase II study of M605110 for axillary osmidrosisaxillary osmidrosisJPRN-jRCT2031220072Tomoyuki Nishiura105